Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Jazz Pharmaceuticals: Clinical Trials & FDA Approval Profile

Jazz Pharmaceuticals (Dublin, IE / Palo Alto, CA) sponsors 43 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 13 active protocols (11 recruiting now), 13 completed protocols, and 11 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)39.5%
Median Closed Enrollment vs National (145 pts)56 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Jazz Pharmaceuticals
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)43
Active Pipeline (Recruiting Now)13 (11)
Completed vs Stopped Early13 / 17 (39.5%)
Median Closed Actual Enrollment56 participants
Physical Hospital Site Disclosure99.3% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals11 (5 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Jazz Pharmaceuticals
Hospital Research SiteLocationShared Protocols
MD Anderson Cancer CenterHouston, TX10
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CA9
Memorial Sloan Kettering Cancer CenterNew York, NY7

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Jazz Pharmaceuticals
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06435429A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the TPhase IIIRECRUITING
NCT06695845A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsPhase IIRECRUITING
NCT05580562ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)Phase IIIRECRUITING
NCT07723963A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic EpilepsyPhase II/IIIRECRUITING
NCT06282575Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Jazz Pharmaceuticals Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI